Pharmaceutical Commerce - September/October 2013

The perfect pharmaceutical product would be a pill or injection that, once taken, has a near-immediate beneficial effect.

For specialty pharmaceuticals, the connection between manufacturer, payer and patient is the rising crop of hub services

State-by-state, plan-by-plan analysis from CVS Caremark highlights multibillion-dollar savings if adherence rates are improved

Essential for approving some new products, biomarkers are becoming integrated with patient therapies

Come September, all eyes will be on federal legislation that is close to final passage

Company will provide services to manage data and terms of sales contracts

What are the risks of future 'pay for delay' settlements between branded and generic manufacturers?

Regardless of how pending US legislation is resolved, manufacturers need to move ahead

Vaccine administration is shifting from multidose vials to prefilled syringes for a host of important safety and economic considerations

Risk Evaluation & Mitigation Strategy (REMS) programs are evolving, with new complexities for compliance managers

Real business value arises from going beyond simple regulatory compliance for California's e-pedigree mandate

Why cloud-based software applications require a new training model